Shuffling the JAKs: playing a new card in chronic GVHD
Julie R Boiko, Paul A Carpenter · 2026
Read Shuffling the JAKs: playing a new card in chronic GVHD by Julie R Boiko, Paul A Carpenter (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13543950.txt.
Description
Julie Boiko and Paul Carpenter comment on a trial of the drug baricitinib for chronic graft-versus-host disease that resists standard care. Their 2026 commentary runs beside the phase 1/2 study in the same journal issue. The disease strikes up to thirty percent of stem cell transplant survivors, scarring organs from eyes to liver.
Most patients move past first-line steroids to later drugs, and four newer agents won approval in the past decade. Baricitinib blocks JAK enzymes, which relay immune signals inside cells. The trial found it safe and effective after prior therapy failed. The commentators place the result in the wider JAK drug family. They frame the study as a fresh card for a long treatment road.
Catalog record
| CREATOR | Julie R Boiko, Paul A Carpenter |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |